Medical imaging infrastructure platform Scan.com has closed a $220 million round to build the largest medical imaging network in the US, the company announced on Monday.
The massive capital influx comes on the heels of explosive growth for the company, which doubled its revenue over the past year to cross a $165 million annualized run rate. The funding will be used to expand Scan.com’s footprint across the United States, targeting a highly fragmented $100 billion market currently hindered by scheduling delays and opaque pricing.
The $220 million funding round comprised a $90 million Series C round and a $130 million debt facility.
Global Expansion Plans
The $90 million equity portion of the round was led by Noteus Partners, with additional participation from Aviva, Concord Health Partners, YZR Capital, and Oxford Capital. An additional $130 million in debt facilities was secured from VerisFi Capital and Atempo Growth to support upcoming mergers, acquisitions, and working capital.
Initially launched in the UK in 2017 as National MRI Scan, it rebranded to Scan.com in 2022 to spearhead its international expansion. To date, the company’s network has facilitated care for more than 900,000 patients globally.
Rebuild Fragmented US Medical Imaging Market
Unlike traditional, static provider directories, Scan.com integrates live, two-way scheduling directly into the electronic medical records (EMRs) of independent imaging facilities. This allows third-party administrators, health plans, employers, and digital health apps to plug into nationwide imaging availability using a single API.
The platform utilizes embedded artificial intelligence to match patient referrals against live availability, local pricing, and specific clinical subspecialties. AI also automates the paperwork and routes finished imaging reports directly to specialized radiologists, yielding a typical turnaround time of under 48 hours. Human care guides remain involved to assist patients throughout the scheduling process.
Digital health startups secured $20+ billion VC funding so far this year. More recently, Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, raised $20 million in a Series B financing.
In another deal, Sydney, Australia-based medical imaging startup Vexev has announced it has raised $6 million in new funding to accelerate the path to FDA 510(k) clearance and U.S. commercialization of VxWave Ultrasound Imaging System, its robotic tomographic ultrasound platform, designed to improve access to standardized vascular imaging.